A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) or JNJ-40346527 in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy
Latest Information Update: 02 Feb 2024
Price :
$35 *
At a glance
- Drugs Daratumumab (Primary) ; Edicotinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 30 Jan 2024 Status changed from active, no longer recruiting to completed.
- 30 Nov 2023 Planned End Date changed from 15 Dec 2023 to 1 Jul 2024.
- 30 Nov 2023 Planned primary completion date changed from 15 Dec 2023 to 1 Jul 2024.